small
interf
rna
sirna
potent
molecul
capabl
block
gene
express
enter
cell
cytoplasm
despit
strong
efficaci
need
carri
nanoscal
deliveri
system
protect
degrad
biolog
fluid
increas
cellular
uptak
favor
subcellular
distribut
sever
studi
highlight
potenti
local
pulmonari
deliveri
sirna
treatment
lung
diseas
purpos
nanoscal
deliveri
system
address
target
passiv
activ
target
cell
review
discuss
possibl
approach
lung
deliveri
nanoscal
particl
carri
sirna
sinc
discoveri
mechan
rna
interfer
via
small
interf
rna
sirna
develop
rapidli
power
tool
molecular
biolog
studi
downregul
gene
express
due
high
effici
select
sirna
becam
rapidli
interest
medic
applic
like
treatment
sever
diseas
number
potenti
applic
target
local
deliveri
sirna
lung
includ
treatment
inflammatori
immun
infecti
diseas
cystic
fibrosi
cf
cancer
howev
sirna
face
obstacl
success
applic
nucleotidebas
therapeut
like
plasmid
dna
antisens
oligonucleotid
ie
poor
cellular
uptak
stabil
serum
lack
select
target
tissu
therefor
carrier
featur
nanoparticul
deliveri
system
appli
address
limit
encapsul
specif
target
lung
cancer
cell
thu
offer
possibl
improv
treatment
lung
diseas
review
focus
local
deliveri
sirna
lung
describ
differ
barrier
stateoftheart
way
circumv
sirna
discov
show
introduct
long
doublestrand
rna
dsrna
varieti
host
could
induc
posttranscript
silenc
homolog
host
gene
andor
transgen
within
intracellular
compart
long
dsrna
molecul
metabol
small
nucleotid
interf
rna
action
endogen
ribonucleas
dsrnaspecif
rnase
iii
enzym
dicer
sirna
molecul
assembl
multiprotein
complex
term
rnainduc
silenc
complex
risc
figur
function
risc
contain
four
differ
subunit
includ
helicas
exonucleas
endonucleas
homolog
search
domain
sirna
bind
risc
duplex
sirna
unwound
helicas
result
two
singl
strand
figur
allow
antisens
strand
bind
target
rna
molecul
figur
endonucleas
hydrolyz
target
mrna
homolog
site
antisens
strand
bound
rna
interfer
antisens
mechan
action
ultim
singl
strand
rna
molecul
bind
target
rna
molecul
watsoncrick
base
pair
rule
follow
bind
cleavag
enzym
present
risc
call
argonaut
degrad
target
rna
mechan
make
feasibl
use
small
doubl
strand
sirna
therapeut
instead
asodn
sirnamedi
silenc
occur
product
cleav
releas
degrad
allow
risc
complex
interact
molecul
mrna
pool
also
shown
small
rna
call
mirna
microrna
caus
gene
silenc
human
well
caenorhabd
elegan
drosophila
melanogast
plant
mirna
process
extend
rna
hairpin
wherea
sirna
produc
rang
rna
precursor
viral
transposon
rna
transgen
mechan
sirna
mirna
rna
interfer
similar
exampl
synthesi
relat
activ
dicer
although
signific
differ
sirna
cleav
mrna
wherea
mirna
case
translationali
repress
mrna
direct
instil
sirna
lung
offer
sever
import
benefit
drug
desir
effect
achiev
total
dose
consider
lower
requir
system
administr
result
lower
risk
toxic
reduc
advers
effect
also
instil
sirna
instanc
aerosol
intratrach
administr
offer
direct
access
lung
epitheli
cell
import
cell
type
varieti
pulmonari
disord
viru
infect
malign
cell
respiratori
tract
achiev
via
system
administr
final
case
cancer
treatment
specif
sirna
would
also
result
much
lower
side
effect
compar
convent
chemotherapi
review
focu
local
deliveri
airway
sirna
larg
molecular
weight
molecul
ioniz
hydrophil
therefor
despit
larg
interest
present
hurdl
vivo
administr
tabl
inde
even
lung
administr
aerosol
solut
reach
site
close
target
vivo
applic
sirna
limit
appar
sirna
instabl
biolog
fluid
inadequ
cellular
uptak
tabl
biolog
fluid
sirna
halflif
short
vari
second
minut
predomin
due
rapid
degrad
endogen
rnase
rapid
clearanc
reach
cellular
target
sirna
need
cross
cellular
membran
neg
charg
size
incub
unmodifi
free
sirna
mammalian
cell
result
effect
knockdown
target
gene
reason
challeng
innov
requir
effect
sirnamedi
therapi
lung
diseas
target
sirna
specif
lung
cell
popul
use
adequ
deliveri
system
allow
deliveri
relev
intracellular
compart
guarante
protect
degrad
system
combin
adequ
intracellular
deliveri
permit
lung
deliveri
either
aerosol
dri
powder
first
obstacl
deliveri
resist
respiratori
mucu
alveolar
fluid
lung
surfact
tabl
inde
larg
airway
continu
renew
mucu
layer
constitut
barrier
assur
defenc
inhal
materi
mucu
compos
mainli
water
mucin
long
flexibl
highli
glycosyl
protein
constitut
around
total
weight
whole
mucu
mucu
trap
inhal
materi
effect
remov
respiratori
tract
toward
upper
end
tracheal
tube
via
mucociliari
clearanc
process
complex
mechan
guarante
lung
integr
physiolog
condit
undergo
import
chang
associ
patholog
diseas
case
inhal
variou
toxic
compound
chronic
disord
respiratori
tract
asthma
cystic
fibrosi
well
exposur
cigarett
smoke
pollut
urban
particular
matter
associ
impair
barrier
function
chang
composit
mucu
layer
one
barrier
size
inhal
materi
lung
deliveri
geometr
diamet
particl
shape
densiti
taken
account
result
call
aerodynam
diamet
ad
ad
particl
affect
magnitud
forc
act
inerti
gravit
effect
increas
increas
particl
size
diffus
produc
larger
displac
particl
size
decreas
figur
larg
particl
ad
usual
impact
airway
wall
bifurc
usual
deposit
higher
airway
back
throat
pharynx
ad
particl
rang
subject
sediment
gravit
forc
occur
smaller
airway
respiratori
bronchiol
figur
optim
particl
size
effici
deposit
lower
respiratori
tract
consid
figur
movement
smaller
particl
aerodynam
diamet
control
brownian
motion
particl
size
decreas
deposit
lung
increas
due
increas
mobil
diffus
howev
nanoparticl
less
nm
appear
settl
effect
alveolar
region
fraction
deposit
around
diamet
get
larger
nanoscal
rang
high
proport
exhal
effort
enhanc
gene
silenc
variou
nonvir
nanoscal
deliveri
system
develop
sirna
deliveri
larg
part
summar
tabl
ii
base
liposom
polymer
deliveri
system
system
develop
purpos
size
one
sever
hundr
nanomet
thu
sirna
must
deliv
cytoplasm
order
activ
silenc
obtain
enhanc
green
fluoresc
protein
egfp
tnfa
tumour
necrosi
factor
freezedri
chitosansirna
nanoparticl
express
egfp
tnfa
express
raw
murin
macrophag
cell
line
egfp
knockdown
effici
increas
sirna
concentr
depend
presenc
sucros
lyoprotect
chitosan
particl
yield
specif
tnfa
knockdown
particl
form
lipid
luficeras
express
silenc
increas
presenc
endosomolyt
peptid
photochem
intern
agent
luciferas
pvaplga
nanoparticl
luciferas
knockdown
minor
cytotox
vivo
experi
cation
dotap
lipid
mice
intratrach
higher
peak
concentr
longer
retent
sirna
lung
compar
system
administr
b
galactosidas
cation
lipid
genzym
gl
mice
intratrach
reduc
bgal
mrna
level
airway
epithelium
protein
express
sparc
matricellular
protein
cation
lipid
dharmafect
miceinduc
fibrosi
intratrach
sparc
sirna
reduc
gene
protein
express
collagen
type
fibroblast
lung
fibrosi
induc
bleomycin
reduc
sparc
sirna
accompani
inhibit
connect
tissu
growth
factor
express
tissu
highli
conserv
region
nucleoprotein
acid
polymeras
influenza
virus
cation
lipid
oligofectamin
invitrogen
deliveri
sirna
reduc
lung
viru
titer
infect
mice
protect
specif
mediat
antivir
ifn
respons
respiratori
syncyti
viru
rsv
p
protein
parainfluenza
viru
piv
type
p
protein
sever
commerci
avail
cation
lipid
includ
dotap
n
propyl
n
n
ntrimethylammonium
methylsulf
dotma
n
propyl
n
n
ntrimethylammonium
chlorid
select
appli
deliveri
nucleic
acid
type
plasmid
antisens
oligonucleotid
sirna
time
research
still
design
synthes
new
lipid
mostli
reduc
advers
effect
describ
first
cation
lipid
cation
lipid
ad
excess
nucleic
acid
form
posit
charg
lipoplex
strongli
interact
neg
charg
cell
membran
facilit
endocytosi
cytoplasm
deliveri
dioleylphosphatidylethanolamin
dope
lipid
helper
gener
associ
cation
lipid
sinc
particip
format
complex
nucleic
acid
facilit
endosom
membran
disrupt
form
hexagon
phase
acid
ph
endosom
strategi
involv
coval
attach
target
ligand
extrem
poli
ethylen
glycol
peg
chain
graft
onto
liposom
also
explor
ligand
specif
promot
intracellular
accumul
nucleic
acidcontain
lipid
particl
target
cell
lead
improv
gene
silenc
regard
lung
deliveri
cation
liposom
carri
sirna
abil
aerosol
shown
vitro
deliv
intracellularli
sirna
human
lung
cancer
cell
line
human
bronchial
epitheli
cell
type
ii
rat
alveolar
epitheli
cell
nevertheless
liposomebas
carrier
still
face
challeng
optim
sirna
deliveri
particl
may
inadequ
associ
system
administr
intrins
problem
nonspecif
interact
blood
compon
improv
test
inclus
anion
charg
peg
give
greater
colloid
stabil
presenc
serum
howev
cover
lipoplex
peg
reduc
aggreg
decreas
transfect
effici
observ
vitro
therefor
import
find
way
achiev
target
lung
cell
design
hyaluron
acid
ha
coat
lipoplex
target
deliveri
cancer
cell
overexpress
ha
bind
receptor
approach
base
properti
ha
besid
endogen
polym
fulfil
import
mechan
structur
function
interact
princip
cell
surfac
receptor
latter
play
import
role
cellcellcellmatrix
interact
cell
adhes
migrat
signal
transduct
extracellular
intracellular
compart
sirna
transfect
improv
hamodifi
liposom
posit
cell
cell
display
receptor
santo
et
al
design
lipoplex
bear
target
ligand
antagonist
g
substanc
p
analogu
competit
inhibit
basal
neuropeptidestimul
growth
differ
smallcel
lung
cancer
sclc
target
vesicl
show
increas
intern
sclc
well
tumor
cell
microvascular
endotheli
cell
improv
cellular
associ
correl
enhanc
downregul
target
absenc
downregul
due
inadequ
releas
nucleic
acid
endocyt
pathway
presenc
mol
peg
incorpor
slp
formul
andor
absenc
membran
destabil
fusogen
lipid
improv
sirna
deliveri
chen
et
al
develop
promis
novel
nonglycerol
base
cation
lipid
dsgla
n
n
aminoethyl
ammonium
chlorid
formul
lipidpolycationdna
lpd
nanoparticl
contain
dotap
target
peg
tether
anisamid
aa
new
lipid
contain
guanidinium
lysin
residu
cation
head
group
chosen
due
fact
guanidinium
group
capabl
form
hydrogen
bond
nucleic
acid
base
thu
enhanc
capac
deliv
plasmid
sirna
lysin
group
select
decreas
cytotox
observ
commerci
lipid
dotap
contain
lpd
nanoparticl
previous
describ
author
presenc
dsgla
aabear
lpd
found
decreas
extracellular
signalregul
kinas
activ
cell
lipid
without
guanidin
group
caus
inhibit
activ
contrari
due
antiapoptop
effect
dotap
increas
activ
observ
among
lipid
system
develop
treat
lung
cancer
pulmonari
diseas
administ
anim
model
local
administr
either
intranas
intratrach
garbuzenko
et
al
compar
intratrach
vs
intraven
deliveri
dotapsirna
lipoplex
mice
intratrach
administr
led
higher
sirna
peak
concentr
much
longer
retent
liposomesirna
lung
compar
system
administr
anoth
experi
cation
lipid
genzym
mediat
uptak
sirna
airway
epithelium
vivo
mice
sirna
complex
result
suspens
place
singl
bolu
nasal
caviti
rapidli
snif
lung
follow
vivo
lung
transfect
sirna
visibl
alveolar
macrophag
sirna
target
reduc
mrna
level
airway
epithelium
mice
shown
rtpcr
howev
insuffici
reduc
protein
express
anoth
experi
mice
induc
skin
lung
fibrosi
bleomycin
follow
sparc
sirna
treatment
subcutan
inject
intratrach
instil
respect
use
dharmafect
transfect
reagent
sparc
secret
protein
acid
rich
cystein
compon
extracellular
matrix
report
biomark
fibrosi
interstiti
pulmonari
fibrosi
treatment
shown
lung
fibrosi
induc
bleomycin
markedli
reduc
treatment
sparc
sirna
antifibrot
effect
sparc
sirna
vivo
accompani
inhibit
connect
growth
factor
ctgf
express
tissu
lung
distribut
intratrach
inject
fluoresc
sirna
show
intens
fluoresc
distribut
within
epitheli
cell
bronchi
bronchiol
weak
fluoresc
detect
parenchyma
unclear
far
differ
lung
distribut
observ
studi
physicochem
properti
complex
size
charg
surfac
properti
might
play
import
role
distribut
complex
compris
oligofectamin
sirna
specif
highli
conserv
region
nucleoprotein
acid
polymeras
found
inhibit
influenza
viru
replic
vivo
intranas
administr
mice
inhibit
obtain
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
use
sirna
viral
gene
instil
intranas
mous
associ
transfect
reagent
transittko
final
suspens
sirna
without
transfect
reagent
lipofectamin
administ
intranas
vivo
murin
model
equin
herp
viru
type
infect
use
sirna
although
administr
free
sirna
induc
protect
clinic
sign
like
weight
loss
signific
differ
could
observ
effect
sirna
complex
transfect
reagent
lipofectamin
buffer
pb
agre
report
activ
intranas
administ
free
sirna
variou
anim
model
clearli
demonstr
case
superior
lipoplex
final
recent
studi
demonstr
inflammatori
properti
lipoplex
carri
sirna
among
variou
sirna
deliveri
system
consid
pulmonari
applic
nanoparticl
nanoscal
carrier
present
sever
advantag
treatment
respiratori
diseas
prolong
drug
releas
cell
specif
target
drug
deliveri
modifi
biolog
distribut
therapeut
agent
cellular
organ
level
nanoparticl
compos
polym
show
assur
fulfil
stringent
requir
place
deliveri
system
target
specif
site
cell
popul
lung
releas
drug
predetermin
manner
degrad
within
accept
period
time
moreov
studi
use
inhal
nanoparticl
dispers
aqueou
droplet
suggest
mucu
clearanc
overcom
nanoparticl
drug
effici
transport
respiratori
epithelium
sever
polym
nanoparticl
system
develop
enhanc
intracellular
deliveri
nucleic
acid
cation
lipid
physiolog
ph
sirna
electrostat
interact
cation
charg
polym
form
polyplex
simpli
mix
compon
optim
condit
posit
charg
either
come
solubl
cation
polym
cation
nanoparticl
complex
gener
possess
global
posit
surfac
charg
get
easili
attach
neg
charg
cell
surfac
subsequ
undergo
endocytosi
one
main
polym
use
polyethyleneimin
pei
branch
polym
high
cation
potenti
complex
form
nucleic
acid
pei
usual
stabl
dispers
noncoval
net
posit
charg
allow
interact
neg
charg
cell
membran
follow
intern
endocytosi
deliveri
nucleic
acid
cytoplasm
occur
proton
spong
effect
proton
numer
amino
group
polym
caus
osmot
ruptur
endosom
cytosol
releas
nucleic
acid
addit
complex
sirna
effici
protect
degrad
vitro
presenc
rnase
vivo
presenc
serum
nucleas
consequ
pei
employ
sever
studi
effici
sirna
deliveri
vitro
vivo
lin
et
al
test
linear
pei
form
cation
complex
sirna
target
cyclin
indispens
protein
cell
mitosi
treatment
sirna
alon
lung
cancer
cell
popul
phase
cell
cycl
increas
around
compar
control
wherea
cell
treat
peisirna
complex
signific
increas
around
indic
better
arrest
cell
mitosi
phase
cell
cycl
treatment
complex
bolcatobellemin
et
al
use
linear
pei
format
complex
modifi
sirna
structur
ad
short
complementari
overhang
make
sirna
bind
form
larg
genelik
structur
new
sticki
overhang
peisirna
complex
show
increas
stabil
improv
rnase
protect
gene
silenc
lung
cancer
cell
linear
pei
capabl
provid
high
effici
system
gene
deliveri
lung
branch
pei
associ
higher
level
acut
toxic
inde
higher
molecular
weight
pei
relat
increas
cytotox
due
aggreg
polym
outer
cell
membran
therebi
induc
necrosi
also
pei
toxic
might
caus
rapid
adsorpt
plasma
protein
onto
posit
charg
polym
lead
aggreg
regard
sirna
beyerl
et
al
show
toxic
also
depend
cell
type
thoma
et
al
found
linear
fulli
deacyl
pei
kda
kda
effect
lung
deliveri
cytotox
transfect
effici
pei
directli
proport
molecular
weight
effort
reduc
toxic
improv
stabil
polyplex
made
synthesi
pei
graft
copolym
linear
peg
modifi
pei
system
poli
ester
pae
compos
low
molecular
weight
pei
peg
complex
sirna
complex
shown
transfect
lung
cancer
cell
sirna
target
enhanc
green
fluoresc
protein
egfp
achiev
silenc
higher
standard
kda
pei
complex
subsequ
studi
author
combin
advantag
chitosan
anoth
cation
polym
detail
see
modifi
pei
system
synthes
chitosangraftpei
chigpei
copolym
compos
chitosan
low
molecular
weight
pei
chigpei
carrier
complex
sirna
silenc
egfp
express
approxim
time
pei
cell
carrier
also
use
studi
silenc
protein
express
protein
vital
role
lung
cancer
sinc
overexpress
relat
mechan
cancer
cell
surviv
prolifer
metastasi
effici
knockdown
mrna
well
decreas
protein
express
observ
use
new
carrier
also
addit
peptid
hivtat
cation
pegpei
copolym
studi
enhanc
transfect
effici
bronchial
cell
vitro
recent
noninvas
aerosol
sirna
deliveri
system
develop
lung
cancer
treatment
degrad
peipeg
copolym
synthes
reaction
lowmolecular
weight
pei
peg
diacryl
aerosol
poli
ester
amin
sirna
complex
deliv
mice
urethaneinduc
lung
cancer
noseonli
inhal
system
follow
aerosol
deliveri
twice
weekli
week
sirna
deliv
complex
poli
ester
amin
show
downregul
akt
relat
signal
inhibit
progress
tumor
lung
cancer
model
mice
besid
pei
chitosan
natur
polysaccharid
mucoadhes
mucoperm
two
qualiti
advantag
target
deliveri
sirna
respiratori
tract
addit
well
toler
biodegrad
form
cation
complex
nucleic
acid
chitosan
effect
sirna
deliveri
gene
silenc
low
toxic
interest
studi
high
degre
deacetyl
high
chitosan
molecular
weight
identifi
liu
et
al
import
paramet
effici
sirnamedi
knockdown
thu
highlight
import
polym
chemic
properti
optim
gene
silenc
use
chitosansirna
nanoparticl
andersen
et
al
deliv
chitosansirna
nanoparticl
target
enhanc
green
fluoresc
protein
egfp
found
egfp
knockdown
effici
increas
sirna
concentr
could
achiev
use
freezedri
nanoparticl
lyophil
directli
within
cell
cultur
dish
onto
surfac
use
later
simpli
ad
cell
suspens
directli
low
sirna
concentr
nm
highest
knockdown
obtain
rel
high
sucros
concentr
use
cryoprotect
knockdown
sucros
wherea
high
sirna
concentr
nm
sucros
suffici
reach
maximum
knock
effici
compar
lipoplex
use
transittko
freezedri
transittkosirna
effect
chitosansirna
concentr
test
although
chitosan
particl
yield
specif
knockdown
particl
form
lipid
also
exhibit
significantli
lower
viabil
approxim
compar
chitosansirna
nanoparticl
cation
polym
use
nguyen
et
al
design
branch
biodegrad
polyest
consist
tertiaryaminemodifi
pla
backbon
graft
plga
polym
previous
found
show
high
transfect
effici
superior
biocompat
compar
pei
rapid
degrad
rate
low
acut
toxic
inflammatori
respons
pulmonari
applic
nguyen
et
al
found
small
sirna
dosag
pmol
necessari
achiev
aim
luciferas
knockdown
human
lung
carcinoma
cell
minor
cytotox
also
polym
ratio
nebul
nanoparticl
display
compar
knockdown
effici
nonnebul
sampl
varkouhi
et
al
evalu
genesilenc
activ
two
enzymaticallydegrad
design
polym
trimethyl
chitosan
tmc
phpmamppm
poli
methacrylamid
methanol
compound
show
rather
import
silenc
effect
higher
current
surfact
less
toxic
reach
valu
increas
presenc
endosomolyt
peptid
photochem
intern
agent
anoth
establish
approach
lung
deliveri
sirna
involv
poli
lacticcoglycol
acid
plga
nanoparticl
plga
approv
human
use
food
drug
administr
fda
sever
plgabas
formul
receiv
worldwid
market
approv
synthet
biodegrad
polym
shown
use
drug
deliveri
formul
good
biocompat
cellular
uptak
control
releas
characterist
also
high
stabil
nebul
accord
campolongo
luo
plga
nanoparticl
attract
much
attent
sinc
assum
meet
criteria
requir
success
sirna
deliveri
suffici
small
effici
tissu
penetr
cellular
uptak
ii
sirna
entrap
plga
matrix
offer
physic
protect
rnase
activ
well
favor
colloid
stabil
system
iii
plga
particl
gener
possess
excel
control
alter
degrad
profil
allow
drug
releas
span
day
year
depend
molecular
weight
composit
block
copolym
structur
nanoparticl
even
though
regard
nucleotid
encapsul
formul
plga
nanoparticl
also
present
challeng
one
difficult
load
smaller
nucleic
acid
molecul
like
sirna
plga
nanoparticl
obtain
high
load
encapsul
effici
use
classic
prepar
method
low
molecular
weight
compound
sirna
easili
leak
inner
water
phase
outer
water
phase
prepar
due
rel
low
molecular
weight
hydrophil
charact
electrostat
repuls
forc
present
phosphat
group
sirna
backbon
anion
acid
group
plga
polym
also
degrad
plga
lead
format
acid
product
lactic
glycol
acid
caus
dna
degrad
damag
optim
paramet
prepar
sirnaload
plga
nanoparticl
doubl
emuls
solvent
evapor
method
studi
cun
et
al
formul
prepar
process
paramet
ration
optim
understand
effect
paramet
volum
ratio
inner
water
phase
oil
phase
ii
plga
concentr
iii
sonic
time
primari
emulsif
iv
sirna
load
v
amount
acetyl
bovin
serum
albumin
acbsa
ad
inner
water
phase
stabil
primari
emuls
plga
concentr
volum
ratio
signific
main
effect
surprisingli
sirna
load
found
contribut
significantli
encapsul
effici
suggest
explan
individu
effect
increas
plga
concentr
result
stabil
primari
emuls
limit
diffus
sirna
organ
phase
due
increas
viscos
organ
phase
higher
inner
water
phase
volum
reduc
concentr
gradient
inner
outer
water
phase
calcium
phosphat
cap
nanoparticl
also
studi
improv
nucleotid
transfect
cap
well
use
nonvir
vector
vitro
transfect
due
fact
rapidli
dissolv
cytoplasm
acid
ph
present
littl
cell
toxic
recent
li
et
al
combin
advantag
coreshel
nanoparticl
structur
cap
nanoparticl
achiev
prolong
circul
time
elev
endosom
releas
mechan
author
studi
nanoparticl
cap
core
pegphospholipid
coat
target
luciferas
human
lung
cancer
cell
improv
genesilenc
effect
observ
cap
dissolv
low
ph
caus
nanoparticl
deassembl
dissolv
calcium
phosphat
ion
increas
osmot
pressur
caus
endosom
swell
releas
encapsul
sirna
lastli
viruslik
synthet
vector
influenza
viru
envelop
virosom
appli
deliv
sirna
vitro
use
virosom
advantag
antivir
sirna
deliveri
lung
fact
expect
taken
cell
infect
viru
rel
high
effici
certain
type
viral
vector
rel
long
durat
gene
express
also
achiev
howev
progress
virosom
research
hamper
difficulti
manufactur
viral
envelop
ineffici
imposs
repeat
administr
sever
complic
associ
immunogen
oncogen
potenti
welldocu
case
death
jess
gelsing
due
complic
associ
adenovir
vector
highlight
problem
studi
nanoparticl
deliveri
respiratori
system
also
import
whether
administ
aerosol
droplet
dri
powder
mention
earlier
review
studi
aerodynam
diamet
particl
contain
nanoparticl
crucial
optim
deliveri
lower
respiratori
tract
also
characterist
liquid
media
solid
excipi
surround
nanoparticl
influenc
releas
kinet
deposit
airway
thu
time
take
nanoparticl
contact
epitheli
cell
macrophag
group
design
multistag
trojan
deliveri
system
combin
advantag
microspher
ie
long
term
releas
polyplex
ie
enhanc
nucleic
acid
intracellular
penetr
inde
solid
nanoparticul
complex
made
pei
nucleic
acid
encapsul
polym
matrix
odn
complex
pei
improv
encapsul
effici
probabl
electrostat
interact
cation
odn
pei
complex
anion
plga
releas
rate
shown
depend
poros
microparticl
higher
poros
faster
releas
low
porou
particl
shown
deliveri
constantli
nanoparticl
consequ
improv
intracellular
penetr
reach
target
microparticl
consist
aggreg
plga
nanoparticl
surround
hollow
core
develop
use
nonbiodegrad
biodegrad
plga
polym
high
aerodynam
properti
particl
seem
promis
lung
deliveri
nanoparticl
although
lung
deliveri
sirna
repres
import
field
therapeut
applic
need
nanoscal
carrier
essenti
allow
deliveri
varieti
system
shown
effici
vitro
system
base
cation
lipid
cation
polym
abl
complex
sirna
biodegrad
polym
abl
encapsul
sirna
surfacemodifi
function
enhanc
target
properti
nevertheless
vivo
deliveri
also
requir
control
aerosol
formul
nanoparticl
despit
success
experi
report
studi
carri
vivo
show
real
benefit
lung
inhal
nanoparticul
system
research
need
order
better
understand
distribut
particl
lung
administr
